A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Recruiting now

Conditions studied: Relapsed/Refractory Multiple Myeloma (RRMM)

In brief

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Key facts

Study ID

NCT06285318

Run by

Janssen-Cilag Ltd.

People needed

900

Starts

2023-12-18

Expected to finish

2026-09-24

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a documented diagnosis of multiple myeloma
• Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
• Received at least one dose of teclistamab/talquetamab
• Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

You may not qualify if…

• To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
• To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
• Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3

Where it is running

• Hosp. Univ. Virgen de Las Nieves — Granada, Spain (enrolling)
• Hosp. Alvaro Cunqueiro — Vigo, Spain (enrolling)
• Akershus Universitetssykehus — Oslo, Norway (enrolling)
• Hosp. Ntra. Sra. de Sonsoles — Ávila, Spain (enrolling)
• Hosp. Univ. de La Paz — Madrid, Spain (enrolling)
• Hosp. Clinico Univ. de Valencia — Valencia, Spain (enrolling)
• G Papanikolaou Hospital of Thessaloniki — Thessaloniki, Greece (enrolling)
• Aalborg Sygehus Syd — Aalborg, Denmark (enrolling)
• Institut Universitaire du Cancer Toulouse Oncopole — Toulouse, France (enrolling)
• Vestfold Hospital Trust — Tønsberg, Norway (enrolling)
• Hopital Albert Calmette - CHU Lille — Lille, France (enrolling)
• Hosp. Univ. de La Princesa — Madrid, Spain (enrolling)
• University Hospital Hamburg Eppendorf — Hamburg, Germany (enrolling)
• Klinikum Region Hannover Klinikum Siloah — Hanover, Germany (enrolling)
• CHU de Nantes hotel Dieu — Nantes, France (enrolling)
• Ahepa University General Hospital of Thessaloniki — Thessaloniki, Greece (enrolling)
• Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii — Würzburg, Germany (enrolling)
• University Hospital of Alexandroupolis — Alexandroupoli, Greece (enrolling)
• Laiko General Hospital of Athens — Athens, Greece (enrolling)
• Alexandra Hospital — Athens, Greece (enrolling)
• Sygehus Lillebælt, Vejle — Vejle, Denmark (enrolling)
• Ioannina University Hospital — Ioannina, Greece (enrolling)
• University Hospital Of Larissa — Larissa, Greece (enrolling)
• Anticancer Hospital of Thessaloniki Theageneio — Thessaloniki, Greece (enrolling)
• Sahlgrenska University Hospital — Gothenburg, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.